FDA authorizes trial of stem cell eye treatment

02/16/2012 | Modern Medicine

The FDA has cleared StemCells' experimental neural stem cell therapy for use in a Phase I/II clinical trial for dry age-related macular degeneration. The open-label, dose-escalation trial will involve 16 patients. Results of a preclinical study showed the stem cell treatment can protect photoreceptors and save vision in an animal model of retinal disease.

View Full Article in:

Modern Medicine

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC